OSE Immunotherapeutics Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study
July 19, 2021 12:00 ET
|
OSE Immunotherapeutics
NANTES, France, July 19, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announced a voluntary and temporary pause of enrollment and dosing in its ongoing...
OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the First Tranche of the Financing Granted by the European Investment Bank
July 09, 2021 12:00 ET
|
OSE Immunotherapeutics
This financing will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in therapeutic areas with high unmet medical needs.This €10 million payment...
OSE Immunotherapeutics Announces Manufacturing Agreement with Cenexi for Clinical Batches of CoVepiT, OSE’s Multi-Target Second-Generation COVID-19 Vaccine
June 30, 2021 01:30 ET
|
OSE Immunotherapeutics
NANTES, France and FONTENAY-SOUS-BOIS, France, June 30, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) and Cenexi, a French contract development and manufacturing...
OSE Immunotherapeutics Reports on its 2021 Virtual Combined General Shareholder’s Meeting
June 24, 2021 12:00 ET
|
OSE Immunotherapeutics
NANTES, France, June 24, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that all the resolutions submitted to a vote at the Combined General...
OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer
May 27, 2021 12:00 ET
|
OSE Immunotherapeutics
This clinical trial will be sponsored and conducted by the Italian Oncology Foundation FoRT and supported by Bristol Myers Squibb and OSE Immunotherapeutics. The study will explore the strategy of...
OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine
May 26, 2021 01:30 ET
|
OSE Immunotherapeutics
First-in-human study evaluating CoVepiT, a multi-variant T cell COVID-19 vaccine for people at risk and vulnerable populations.CoVepiT is a peptide-based vaccine aiming to induce CD8+T-cell-mediated...
OSE Immunotherapeutics and Boehringer Ingelheim Present Positive Phase 1 Results with First-in-Class SIRPα inhibitor BI 765063 in Advanced Solid Tumors at ASCO 2021
May 20, 2021 01:30 ET
|
OSE Immunotherapeutics
BI 765063, a first-in-class SIRPα inhibitor on the SIRPα/CD47 “Don’t eat me” pathway, is under collaborative development with Boehringer Ingelheim.Data indicate BI 765063 was well tolerated and showed...
OSE Immunotherapeutics Announces €10.7 Million in Additional Public Funding, via Bpifrance, to Finance Further Development of CoVepiT, its Multi-Target and Multi-Variant COVID-19 Vaccine in Phase 1 Clinical Phase
May 18, 2021 01:30 ET
|
OSE Immunotherapeutics
CoVepiT is a SARS-CoV-2 vaccine activating T cell defences through CD8 T cell multi-epitopes.CoVepiT epitopes* are selected from 11 viral protein targets designed to cover all initial and new emerging...
OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation Market
April 26, 2021 12:00 ET
|
OSE Immunotherapeutics
Agreement expands Veloxis’ product portfolio and the continued commitment to improving the lives of transplant patients.OSE Immunotherapeutics to receive up to €315 million in potential...
OSE Immunotherapeutics Announces First Peer-Reviewed Publication in "Science Advances" on OSE-230, its Novel Monoclonal Antibody Agonist Therapy Triggering Resolution of Chronic Inflammation
April 06, 2021 01:30 ET
|
OSE Immunotherapeutics
NANTES, France, April 06, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) announced the first peer-reviewed publication on OSE-230, a novel and innovative approach...